Marlin (Cholin Bitartrate) Brand: Marlin Generic: Cholin Bitartrate Class: Medical Food Supplement Route of administration: Oral Dosage form: Syrup & Tablet Dose: Tablet: 1 tablet daily Syrup: Children: 1 to 2 teaspoon full Adults: 1 to 2 tablespoon full Contraindications: Pregnancy: Cat. C Pack Size: 10 tabs. / 120ml syp. Price: Rs. 750/- Supplement facts: Supplement Amount per serving Citicoline 500mg AnMar specs. 300mg 1. Citicoline Citicoline is the name for cytidine 5′-diphosphocholine (CDP-choline) when this is used as an exogenous sodium salt. In fact, CDP-choline is an endogenous nucleotide naturally found in the body where it is an essential intermediate in the synthesis of the major phospholipid of the cell membranes, phosphatidylcholine (PtdCho). This type of synthesis is called the Kennedy pathway [1]. As a drug, citicoline has been proposed for use in traumatic brain injuries, stroke, vascular dementia, Parkinson’s disease, and brain aging [2] where it has the function of stabilizer of cell membranes and reduces the presence of free radicals [3]. In particular, there is some evidence of a stimulating role of citicoline for the release of dopamine neurotransmitters in the brain [4]. Citicoline, by activating the central cholinergic system, also increases plasma adrenocorticotropic hormone (ACTH) levels and potentiates serum thyrotrophin (TSH) levels. The stimulation of central nicotinic and muscarinic receptors also increases growth hormone (GH) and luteinizing hormone (LH) serum levels [5]. This activity on the cholinergic system is of high therapeutic usefulness in those clinical conditions where alterations of acetylcholine metabolism are considered one of the primary causes of disease [6], eg, Alzheimers Disease (AD). The biological activity attributed to citicoline has suggested a possible role of citicoline on improving memory [7]. Some clinical studies have given evidence to this hypothesis [8] and there is a proposal for studying citicoline in mild cognitive impairment (MCI) with the aim of confirming both its efficacy in these patients and a possible role as a retardant agent for the cognitive deterioration of the eventual subsequent dementia [9]. 1.1. Therapeutic applications of citicoline 1.1.1. Stroke More than 11 000 people, including patients and volunteers have been studied for evaluating citicoline therapeutic effects. 1372 of these patients were included in studies concerning citicoline efficacy in acute ischemic stroke and pooled together in a meta-analysis of these studies [10]. This analysis showed that citicoline increases the probability of a complete recovery after three months from moderate to severe stroke when it is administered within 24 hours from the event, although the odds ratio of improving with citicoline is only 1.33. Citicoline’s therapeutic action has been attributed to its restoring activity of the PtdCho levels which decrease after a stroke [11]. In stroke patients there seems to be a particular problem in efficiently delivering citicoline at high enough blood levels required to be effective, and to avoid those differences in results evidenced between studies done by intravenous (IV) administration of the drug and oral administration, a more effective preparation for the oral administration is suggested [12]. 1.1.2. Vascular dementia The clinical picture of cognitive and behavioural disorders associated with chronic cerebrovascular disorders (CVD) is much less clear-cut and defined than the picture associated with Alzheimer’s dementia. The definition itself of vascular dementia (VD) has been under discussion for a long time and the heterogeneity of the conditions of patients included in this group is probably higher than the similarities between patients [13]. 1.1.3. Correlative studies When attempts are made to identify relevant relationships between neuroimaging and cognitive patterns, most of the studies have not been able to point out consistent and reliable concordance between these two domains [14] primarily because of the low power of these studies due to the small number of cases [15]. There is evidence of different patterns of cognitive deficits in patients with chronic cerebrovascular disorders when it has been possible to differentiate between those with prevalent signs of altered hippocampal volume from those with diffuse alterations in the grey and white matter [16]. Memory deficits are more relevant in the former group and executive function impairment in the latter group. These findings do not overlap with those that emerge when subcortical dementia is studied as an independent clinical entity characterized by defined quantities of leuakariosis. These neuroimaging findings are commonly associated with deficits in executive function, while memory disorders are considered to be a direct function of cortical impairment [17]. In some instances, this apparent contrast among study results was explained by the different origin of the patients included; eg, when patients from stroke clinics are compared with patients from memory clinics, the specificity of relationship between neuroimaging and functional data is much weaker in the latter group [18]. A proposal has been presented that considers subcortical dementia as a specific form of vascular dementia related to a predominantly small vessel pathogenesis. Mixed dementia is then considered as a nonspecific form of vascular dementia and related to prevalent large infarcts pathogenesis associated with cortical primary atrophy [19]. This model points out the need of considering possible different pathogeneses for different forms of vascular encephalopathy, but does not yet help in identifying specific cognitive patterns of decline associated with them. These issues have largely confounded the studies of citicoline. 1.1.4. Population studies In studies aimed to identify the relationship between presence of cerebrovascular disorders and prevalence of cognitive disorders in the general population, signs of vascular pathogenesis such as arterial stiffness or generalized atherosclerosis are consistently related to cognitive deterioration which ranges from mild severity to dementia [20]. 1.1.5. Specificity of cognitive deficits The most common way of defining the specificity of cognitive deficits in vascular dementia is based on comparison with AD patients. Cognitive deficits in these two forms of dementia are consistently found to be more severe in AD patients, while the specificity of deficits in vascular dementia is less clear and more difficult to be replicated in diverse studies. Executive function deficits seem to be more prevalent in vascular dementia, while memory deficits are more typical for AD [21]. Another line of research focuses on the identification of specific predictors of developing vascular dementia in groups of patients characterized by those pathologies which are commonly considered as risk factors for cardiovasculopathies such as diabetes and hypertension. The evidence of slight and not evenly distributed signs of cognitive impairment in hypertensive patients [22] and its relationship with the daily temporal distribution of elevated picks of systolic blood pressure (more than with the level of high blood pressure of picks) [23] can be considered as the evidence of a progressive development of a cerebrovascular pathology even before gross anatomical signs of abnormality can be identified in the brain tissues. These findings provide support for the proposal to introduce early therapeutic intervention in patients with mild signs of cerebrovasculopathy or even with risk factors for it [24]. 1.1.6. Treatment of cognitive deficits Attempts to treat symptoms of decline in cerebrovasculopaties have been made since the first years of the last century [25] starting with niacin and continue today. At the beginning of the 1980s, citicoline was used in these clinical areas after having been already in use in treatment for stroke. In most of the clinical studies with citicoline in VD, memory has been the principal end point in the efficacy evaluation. There is a large experimental database of experimental studies on memory and learning performed on aged animals treated with citicoline. Most of these studies have shown that treatment with citicoline ameliorates cognitive deficits but does not necessarily improve normal cognitive functions [26]. The few studies done on memory in aged human subjects with memory disorders, but no dementia, have underlined the extreme variability of positive outcomes depending on the type of patients and the kind of measures used in the studies. Memory is a very complex and multidimensional variable to quantify in humans and, consequently, results from different studies which have in common the assessment of memory are not necessarily homogeneous and comparable if the specific modality of memory evaluation is not taken into account. We have seen that those studies which are trying to identify specific patterns of memory disorders in vascular dementia are not yet able to define a definite and reliable cognitive model of functioning of these patients. As a consequence, it is almost impossible to try to systematically apply a specific memory parameter for the evaluation of treatment efficacy in this clinical area, as it has been possible for AD. There is a possibility that memory disorders might be contaminated by other disorders attributable to executive function including attention. This problem has been examined by looking for methods of evaluating primary memory deficits as distinct from those secondary to other cognitive impairments external to memory per se [27]. Another relevant problem that emerges from a critical analysis of the current and past literature is the relatively poor reliability of single studies performed on small samples of patients with various forms of vascular dementia (a further level of complexity is derived by the different criteria given to these patients in different periods of time). A metanalysis is the best solution available for circumventing these limitations. In the case of citicoline, a meta-analysis for examining the reliability and validity of effects on memory which have been studied in different ways and types of patients in various studies, could fail to confirm the positive results of the single studies once these data are pooled together. A metanalysis has been performed on the available published and unpublished data obtained from controlled clinical trials done with citicoline. This metanalysis carried out according to the Cochrane Collaboration guidelines is periodically updated in order to include all the studies available [28]. Results of the metanalysis are divided by domains. This allows for a comparative analysis between different areas of assessment; for example, attention and memory. It is possible to verify the homogeneity of results within each domain. Memory is one of the domains in this analysis and includes results from 884 patients. While studies in this domain include other types of patients as well as cerebrovascular patients, there was no heterogeneity among their results. This indicated that the effect of citicoline on memory was significantly different from the placebo effect, and did not specifically depend on the pathogenesis of the cerebral disorder (effect size 0.19; confidence interval [CI] 95% 0.06, 0.32; p<0.005). In fact, when only cerebrovascular disorders studies were pooled together (for a total of 675 patients), the homogeneity and entity of results was about the same (effect size 0.22; CI 95% 0.07, 0.37; p<0.004). Within the domain that deals with behavior control and competence (a total of 814 patients), there was a citicoline effect significantly different from placebo and independent from type of measure and pathology examined (effect size −0.26; CI 95% −0.49, −0.04; p<0.004). These results coupled with those of the domain clinical evaluation of improvement concerning a total of 217 patients (effect size determined as the odds ratio of improving under active treatment 8.89; CI 95% 5.19, 15.22; p<0.001) showed that the cognitive effects of citicoline are clearly evident at the behavioral level and can be easily appreciated with a clinical observation of patients irrespective of the functional paradigm used to measure them. The attention domain, even though based on a substantial number of 790 patients, revealed a large amount of variance because of the large individual differences. These data did not permit an interpretation of how much of the results evidenced by memory measures can be considered as specific of the “true” memory processes or as secondary to an effect on other cognitive components of the cognitive decline. Finally, the tolerability of citicoline has never constituted a problem whatever the modality of administration or the dosage. 1.2. Conclusions Treatment in patients with disorders attributed to a cerebrovascular pathogenesis has a long history. Unfortunately, many problems are still unresolved, including the taxonomy of these disorders and a definition of cognitive pattern of decline to be associated to this taxonomy. These intrinsic problems have not helped to develop accepted methods of research and treatment for these patients. Despite these difficulties and elements of confusion between different clinical studies performed at different periods of time, citicoline has emerged as a valid treatment for patients with chronic cerebrovascular disorders or with memory problems References: 1. Fernandez-Murray JP, McMaster CR. Glycerophosphocholine catabolism as a new route for choline formation for phosphatidylcholine synthesis by Kennedy pathway. J Biol Chem. 2005;46:38290–6.[PubMed] 2. Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002;17:314–21. [PubMed] 3. Zweifler RM. Membrane stabilizer: citicoline. Curr Med Res Opin. 2002;18(Suppl 2):14–17.[PubMed] 4. Fonlupt P, Martinet M, Pacheco H. Effect of CDP-choline on dopamine metabolism in central nervous system. In: Zappia V, Kennedy EP, Nilsson BI, et al., editors. Novel biochemical, pharmacological, and clinical aspects of CDP-choline. New York: Elsevier; Sci: 1985. pp. 169–77. 5. Cavum S, Savci V. CDP.choline increases plasma ACTH and potentiates the stimulated release of GH, TSH, and LH: the cholinergic involvement. Fundam Clin Pharmacol. 2004;18:513–23.[PubMed] 6. Shen ZX. Brain cholinesterases: III. Future perspectives of AD research and clinical practice. Med Hypotheses. 2004;63:298–307. [PubMed] 7. McDaniel MA, Maier SF, Einstein GO. “Brain-specific” nutrients: a memory cure? Nutrition. 2003;19:957–75. [PubMed] 8. Agnoli A, Bruno G, Fioravanti M. Therapeutic approach to senile memory impairment: a double-blind clinical trial with CDP-choline. In: Wurtman RJ, Corkin S, Growdon JH, et al., editors. Alzheimer’s disease: proceedings of the fifth meeting of the International Study Group in the Pharmacology of Memory Disorders Associated with Aging. Boston: Birkhauser; 1986. pp. 649–54. 9. Abad-Santos F, Novalbos-Reina J, Gallego-Sandin S, et al. Tratamiento del deterioro cognitivo lieve: utilidad de la citicolina. Rev Neurol. 2002;35:675–82. [PubMed] 10. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic strike: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850–7. [PubMed] 11. Rao AM, Hatcher JF, Larsen EC, et al. CDP-choline significantly restores the phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP-phosphocholine cytidylyltransferase after stroke. J Biol Chem. 2006;281:6718–25. [PubMed] 12. Rao AM, Hatcher JF. Cytidine-5’-Diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res. 2005;30:15–23. [PMC free article] [PubMed] 13. Wallin A, Milos V, Sjogren M, et al. Classification and subtypes of vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):27–37. [PubMed] 14. Paul RH, Cohen RA, Moser DJ, et al. Clinical correlates of cognitive decline in vascular dementia. Cogn Behav Neurol. 2003;16:40–6. [PubMed] 15. Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (Cytidine Diphosphate Choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis. 2003;16:199–204. [PubMed] 16. Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. Neurology. 2005;65:565–71. [PMC free article] [PubMed] 17. Price CC, Jefferson AL, Merino JG, et al. Subcortical vascular dementia: integrating neuropsychological and neuroradiologic data. Neurology. 2005;65:376–82. [PMC free article][PubMed] 18. Rockwood K, Black SE, Song X, et al. Clinical and radiological subtypes of vascular cognitive impairment in a clinic-based cohort study. J Neurol Sci. 2006;240:7–14. [PubMed] 19. Jellinger KA. Pathology and pathophysiology of vascular cognitive impairment. A critical update. Panminerva Med. 2004;46:217–26. [PubMed] 20. Hanon O, Haulon S, Lenoir H, et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke. 2005;36:2193–7. [PubMed] 21. Traykov L, Baudic S, Raoux N, et al. Patterns of memory and perseverative behavior discriminate early Alzheimer’s disease from subcortical vascular dementia. J Neurol Sci. 2005:229–230. 75–9.[PubMed] 22. Fioravanti M, Agazzani D, D’Ilario D, et al. Relationship between hypertension and early indicators of cognitive decline. Dementia. 1991;2:51–6. 23. Fioravanti M, Nacca D, Golfieri B, et al. The relevance of continuous blood pressure monitoring in examining the relationship of memory efficiency with blood pressure characteristics. Physiol Behav. 1996;59:1077–84. [PubMed] 24. Schindler RJ. Dementia with cerebrovascular disease: the benefits of early treatment. Eur J Neurol. 2005;12(suppl 3):17–21. [PubMed] 25. Fioravanti M. History of symptomatic therapy in vascular dementia. Int Psychogeriatr. 2003;15(suppl 1):177–81. [PubMed] 26. Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Altern Med Rev. 2004;9:17–31. [PubMed] 27. Fioravanti M, Di Cesare F. Memory improvements and pharmacological treatment: a method to distinguish direct effects on memory from secondary effects due to attention improvement. Int Psychogeriatr. 1992;4:119–26. [PubMed] 28. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;18:CD000269. [PubMed]